praluent price cut match issu
regeneron sanofi lower cost praluent begin earli march
follow increas discount announc may order address continu
reimburs pressur howev wonder sni reduc price
praluent dose includ channel vs new dose avail
medicar copay off-set regn/sni
importantli believ sni chose lower list price address high
copay specif medicar part move praluent lower tier importantli
compani provid co-pay assist medicar commerci plan
believ medicar part formulari consid place praluent lower tier given
new discount increas access
lower pt moder praluent estim
lower pt base lower praluent sale
beyond us praluent revenu fall
praluent revenu fall us increas
praluent share begin chang off-set lower price
biotech discov
invent manufactur commerci medicin
treat seriou diseas
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
hold unchang target price februari
data dupix pediatr adregulatori regulatori decis libtayo advanc csccpdufa date eylea npdr patient w/o date dupix adolesc adpdufa date praluent cardiovascular risk reductionpdufa date praluent first-lin hyperlipidemia figur valuat dcf
hold unchang target price februari
free yoy depreci less capit less work capit free firm yoy discount rate pv termin net outstand valu per equityrisk-fre growth ratewacctermin growth ratetvdiscount rate regeneron
hold unchang target price februari
hold unchang target price februari
fy producteyleau ex-u arcalystu ex-u revenues- libtay ex-u revenues- net product sale book praluentu ex-u ww zaltrap- ww us ex-u kevzara- us ex-u dupixent- us atop uncontrol asthma- ex-u atop uncontrol asthma- figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact
canaccord genuiti sale person author analyst whose contact inform appear front page report
hold unchang target price februari
fy bayer collabor technolog net product contract research other- total good option expensegross oper expensesresearch sell gener collabor total oper profit loss incom expens incom expens loss earli extinguish debtpre-tax incom tax rate tax expens benefit net incom loss adjust net net incom loss ep fulli ep fulli share dilut share outstand figur balanc sheet
hold unchang target price februari
fy pharmaceut balanc sheetassetscash cash equival market secur account receiv trade account receiv sanofi account receiv bayer defer tax assets- prepaid expens current asset total current asset restrict cash market secur market secur properti plant equip cost net accumul defer tax asset total asset liabil account payabl accru expens capit leas oblig defer revenu sanofi current portion defer revenu current portion facil leas oblig current portion current total current liabil convert senior notes- defer revenu sanofi defer revenu facil leas oblig long term liabil total liabil commit conting total stockhold equiti total liabil stockhold equiti figur statement cash flow
hold unchang target price februari
fy statement flow net incom adj reconcil net loss net cash use provid oper activities- depreci non-cash compens non-cash interest expense- loss earli extinguish debt- net realiz loss gain market securities- non-cash charg expens defer chang asset liabil decreas increas account increas increas decreas prepaid expens decreas increas defer increas account payabl accru expens total flow purchas market sale matur market purchas restrict market securities- decreas increas restrict cash- capit increas restrict cash- flow repurchas repay note payabl proce connect facil leas oblig payment connect facil leas obligations- net proce issuanc common payment common stock tender employe tax payment connect reduct outstand warrants- net proce issuanc convert debt- proce connect issuanc warrants- payment connect capit leas obligations- payment connect convert debt- payment connect purchas convert note hedges- excess tax benefit stock-bas compensation- repurchas common flow net increas cash cash cash equival begin cash equival end paid interest paid incom tax regeneron
